Methylphenidate and Response to Alcohol Cues
Key facts
- Who runs it
- University of Florida
- Where
- Gainesville, United StatesSee the site
- Trial code
- Status
- Not yet recruiting
- Phase
- Phase 2
- People taking part
- 50 people, planned
- Started
- Oct 2026
- Expected to end
- Aug 2028
- Type of study
- Interventional, 2 groups
- Treatments tested
- Methylphenidate Pill
- Placebo Pill
- Record updated
- 20 August 2026
Who can take part
- Age
- 18 years to 25 years
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 12 criteriaShow less
Who can take part
- Adults ages 18-25 years
- Meets DSM-5 criteria for Alcohol Use Disorder -OR- score on the Alcohol Use Disorders Identification Test (AUDIT) of >=8
- Fluent in English
- Normal or corrected to normal vision
Who cannot take part
- Meets DSM-5 criteria for psychotic disorders, neurological disorders, or substance use disorders other than Alcohol Use Disorder
- Participant routinely uses psychoactive drugs or medications except for non-dependent marijuana or nicotine use (due to common use of these substances in individuals with Alcohol Use Disorder)
- Self-reported history of high blood pressure over 140/90 or consistent readings of 140/90 or above upon arrival for a session
- History of seizure disorder
- Liver disease
- Participant has contraindications for taking methylphenidate
- Participant has contraindications for being in an MRI machine
- Participant is currently pregnant or trying to become pregnant
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 25 years old?
Where in United States
- University of FloridaGainesville, United StatesContact: Amanda Elton, PhDNot yet recruiting
About the trial
What the trial wants to find out
The purpose of this study is to determine whether changes in attention levels related to taking a single dose of a medication called methylphenidate, also known as Ritalin, affects responses to alcohol cues. The study will observe the effects of methylphenidate or a placebo on neural and craving responses to alcohol cues through fMRI and behavioral testing. Participants will be involved in one remote and two in-person sessions.
The 2 groups in the trial
- Crossover 1: methylphenidate, placeboTreatment being tested
methylphenidate (single dose, oral, 20 mg, immediate release) followed by placebo (single dose, oral)
Treatment: Methylphenidate Pill and Placebo Pill
- Crossover 2: placebo, methylphenidateTreatment being tested
placebo (single dose, oral) followed by methylphenidate (single dose, oral, 20 mg, immediate release)
Treatment: Methylphenidate Pill and Placebo Pill
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Attentional Ability and Resilience to Alcohol Use Disorder: Neurocognitive Mechanisms: Protocol Two
- Fit questions
- Built from NCT07306078, who can take part
- Record updated
- 20 August 2026